Eplerenone prevents an increase in serum carboxy‐terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure-Reference-Cited by-同舟云学术

Eplerenone prevents an increase in serum carboxy‐terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure

Published:2020-04-03 Issue:5 Volume:22 Page:901-903
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Stienen Susan¹,Ferreira João Pedro¹,Pitt Bertram²,Cleland John G.³,Pellicori Pierpaolo³,Girerd Nicolas¹,Rossignol Patrick¹,Zannad Faiez¹

Affiliation:

1. Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116 CHRU de Nancy, F‐CRIN INI‐CRCT Nancy France

2. Department of Medicine University of Michigan School of Medicine Ann Arbor Michigan USA

3. Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow and National Heart & Lung Institute, London, UK

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1812

Reference5 articles.

1. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

2. Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure

3. Circulating Biomarkers of Myocardial Fibrosis

4. Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin

5. Stability of Several Biochemical Markers of Bone Metabolism

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protective effect of combined use of standard drug therapy and spironolactone against arrhythmia and heart failure in patients with acute ST-segment elevated myocardial infarction after emergency percutaneous coronary intervention;Tropical Journal of Pharmaceutical Research;2024-09-12

2. The Pathobiology of Myocardial Recovery and Remission: From Animal Models to Clinical Observations in Heart Failure Patients;Methodist DeBakey Cardiovascular Journal;2024

3. Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials;European Journal of Heart Failure;2023-12-28

4. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology;European Journal of Heart Failure;2022-04-21

5. Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial;European Journal of Heart Failure;2021-12-09